Blueprint Medicines Corporation (LON: 0HOJ)

Market Cap	5.73B
Revenue (ttm)	324.12M
Net Income (ttm)	-95.54M
Shares Out	n/a
EPS (ttm)	-1.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	625
Average Volume	326
Open	111.48
Previous Close	109.30
Day's Range	111.48 - 113.24
52-Week Range	42.68 - 113.24
Beta	n/a
RSI	69.83
Earnings Date	Feb 14, 2025

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medul...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2008
• Employees: 655
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HOJ

Financial Performance

In 2023, Blueprint Medicines's revenue was $249.38 million, an increase of 22.22% compared to the previous year's $204.04 million. Losses were -$506.98 million, -9.06% less than in 2022.

Financial numbers in USD